Cyclacel Pharmaceuticals Inc. (CYCC)

Oncology Corporate Profile

Stock Performance

0.4250
0.0050

3 Month Stock History Chart

HQ Location

200 Connell Drive, Suite 1500
Berkeley Heights, NJ 7922

Company Description

Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Website: http://www.cyclacel.com

Brand Generic Indication
Numoisyn® LiquidNumoisyn® Liquid is indicated for the treatment of symptoms of dry mouth. Numoisyn® Liquid relieves the symptoms of dry mouth by enhancing swallowing, improving speech mechanics, and lubricating the oral cavity like natural saliva. Numoisyn Liquid may be used to replace natural saliva when salivary glands are damaged or not functioning. The viscosity is similar to that of natural saliva.
Numoisyn® LozengesNumoisyn® Lozenges are indicated for the treatment of xerostomia (dry mouth). Numoisyn® Lozenges provide temporary relief of dry mouth due to damaged salivary function. Numoisyn® Lozenges are formulated to support the natural protection of teeth provided by saliva so that no damage occurs to teeth with repeated use of the lozenges.
Xclair® CreamXclair® Cream is indicated to manage and relieve the burning, itching, and pain experienced with radiation dermatitis. Xclair® Cream may be used to relieve the pain of firstand second-degree burns.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
sapacitabine / CYC682antimetabolite (oral)1st line metastatic Acute Myelogenous Leukemia (AML)III
sapacitabine / CYC682antimetabolite (oral)Myelodysplastic Syndrome (MDS)II
seliciclib / CYC202cyclin-dependent kinase inhibitor (oral)Nasopharyngeal cancerII
sapacitabine / CYC682antimetabolite (oral)Non Small Cell Lung Cancer (NSCLC)II
sapacitabine (+ decitabine) / CYC682antimetabolite (oral)Acute Myelogenous Leukemia (AML)I
sapacitabine (+ seliciclib) / CYC682 (+ CYC202)antimetabolite (oral)/cyclin-dependent kinase inhibitor (oral)Various cancer typesI
CYC065CDK inhibitorVarious cancer typesPreclinical
CYC140PLK inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.cyclacel.com

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/16/2017 06:18 pm

8/16/2017 06:18 pm

8/16/2017 06:18 pm

8/16/2017 06:18 pm

8/10/2017 12:18 am

8/10/2017 12:18 am

8/10/2017 12:18 am

8/10/2017 12:18 am

8/9/2017 12:18 pm

8/9/2017 12:18 pm

8/9/2017 06:18 am

8/7/2017 12:18 am

8/7/2017 12:18 am

8/7/2017 12:18 am

8/3/2017 12:19 am

7/21/2017 12:18 pm

7/20/2017 06:18 am

5/12/2017 12:17 am

5/11/2017 12:17 pm

5/11/2017 12:17 pm

5/11/2017 12:17 pm